Open Monoclonal Technology Announces OmniAb(TM) License to Seattle Genetics
(Thomson Reuters ONE) -
PALO ALTO, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Open Monoclonal Technology,
Inc. (OMT) today announced a license that provides Seattle Genetics, Inc. with
access to OMT's proprietary OmniRat(®), OmniMouse(®) and OmniFlic(TM) human
antibody generation platforms. Seattle Genetics becomes OMT's 19(th) partner
globally.
Dr. Roland Buelow, OMT founder and CEO, said, "Seattle Genetics is an
established leader in the field of antibody-drug-conjugates. We are pleased to
provide the company with access to OMT's human antibody generation technologies
to accelerate their continued efforts to develop and commercialize innovative
antibody-based therapies for cancer."
About OMT Group
Open Monoclonal Technology, Inc. (OMT), OMT Therapeutics, Inc. (OMTT), and
Recombinant Antibody Technology, Ltd. (RAT) are leaders in genetic engineering
of animals for the generation of mono-, bi- and poly-specific human therapeutic
antibodies, naturally optimized human antibodies(®), and the only group in the
world with four transgenic animal platforms.
OmniRat(®) is the industry's first human monoclonal antibody technology based on
rats. It has a complete immune system with a diverse antibody repertoire and
generates antibodies with human idiotypes as well as wild-type animals make rat
antibodies. OmniMouse(®) is a transgenic mouse that complements OmniRat and
expands epitope coverage. OmniFlic((TM))is an engineered rat with a fixed light
chain for development of bispecific, fully human antibodies. Full-length human
antibodies from these three animals are called OmniAb((TM)). UniRat((TM)) is the
first transgenic rat generating human UniAb(TM)heavy chain-only antibodies and
nanobodies for polyspecific applications.
All four platforms use patented technology, have broad freedom to operate and
deliver fully human antibodies with high affinity, specificity, expression,
solubility and stability. Animals are hosted in master colonies globally by
Charles River Labs and Taconic with backups at Genentech and Roche. OmniAb and
UniAb antibody discovery services are available via Antibody Solutions, OMTT and
Sage Labs in the US, Aldevron and Taconic in Europe and WuXi AppTec in Asia.
OmniAb and UniAb antibodies are available for all applications, indications and
territories. Current partners include Amgen, ARMO, Berlin-Brandenburg Center for
Regenerative Therapies, Caltech, Celgene, Chugai, Five Prime, Genmab, Genentech,
Gloria, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Seattle Genetics, Symphogen,
University of Nottingham and some undisclosed biotech and pharmaceutical
companies.
For more information, please
visit www.omtinc.net, www.omttherapeutics.com, www.ratltd.net or contact Brian
Lundstrom, Chief Business Officer, at +1-775-420-7750 or bl(at)omtinc.net.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Open Monoclonal Technology, Inc. via GlobeNewswire
[HUG#1963118]
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 431151
Anzahl Zeichen: 3629
contact information:
Town:
Palo Alto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Open Monoclonal Technology Announces OmniAb(TM) License to Seattle Genetics"
steht unter der journalistisch-redaktionellen Verantwortung von
Open Monoclonal Technology, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
